

Hiroto Hatabu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7868464/publications.pdf>

Version: 2024-02-01

188
papers

12,433
citations

26630

56
h-index

29157

104
g-index

191
all docs

191
docs citations

191
times ranked

10307
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. <i>Thorax</i> , 2023, 78, 559-565.	5.6	2
2	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. <i>Chest</i> , 2022, 161, 470-482.	0.8	26
3	Vector-Field dynamic X-ray (VF-DXR) using Optical Flow Method. <i>British Journal of Radiology</i> , 2022, 95, 20201210.	2.2	2
4	Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. <i>Chest</i> , 2022, 161, 999-1010.	0.8	8
5	Vector-field dynamic x-ray (VF-DXR) using optical flow method in patients with chronic obstructive pulmonary disease. <i>European Radiology Experimental</i> , 2022, 6, 4.	3.4	1
6	Dark-Field Chest Radiography in the Detection of Emphysema. <i>Radiology</i> , 2022, 303, 128-129.	7.3	0
7	Interstitial lung abnormalities are associated with decreased mean telomere length. <i>European Respiratory Journal</i> , 2022, 60, 2101814.	6.7	8
8	Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. <i>European Journal of Radiology Open</i> , 2022, 9, 100419.	1.6	21
9	Detection of Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction Using Quantitative Chest CT. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 638-640.	5.3	1
10	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 795-805.	5.6	11
11	Screening for preclinical parenchymal lung disease in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 3234-3245.	1.9	14
12	The Proteomic Profile of Interstitial Lung Abnormalities. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 337-346.	5.6	7
13	Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality: The COPD Gene Study. <i>Radiology</i> , 2022, 304, 694-701.	7.3	13
14	Blood gene expression risk profiles and interstitial lung abnormalities: COPD Gene and ECLIPSE cohort studies. <i>Respiratory Research</i> , 2022, 23, .	3.6	2
15	Synopsis from Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders. <i>Chest</i> , 2021, 159, 492-495.	0.8	12
16	The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1149-1157.	5.6	35
17	Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021, 48, 656-663.	2.0	52
18	Imaging Features of Pulmonary Leukemic Infiltration With Comparison of Lymphoid and Myeloid Leukemias. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 164-167.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Spectrum of Pulmonary Fibrosis from Interstitial Lung Abnormality to Usual Interstitial Pneumonia: Importance of Identification and Quantification of Traction Bronchiectasis in Patient Management. Korean Journal of Radiology, 2021, 22, 811.	3.4	20
20	Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study. Cancer Imaging, 2021, 21, 14.	2.8	12
21	Dynamic Chest X-Ray Using a Flat-Panel Detector System: Technique and Applications. Korean Journal of Radiology, 2021, 22, 634.	3.4	22
22	Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study. European Journal of Radiology Open, 2021, 8, 100334.	1.6	15
23	Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). European Journal of Radiology Open, 2021, 8, 100336.	1.6	8
24	Psychological impact of genetic and clinical screening for pulmonary fibrosis on asymptomatic first-degree relatives of affected individuals. Thorax, 2021, 76, 621-623.	5.6	11
25	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Nonâ€Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 501-509.	3.0	4
26	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 550-566.	7.3	53
27	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.8	53
28	Pulmonary Functional Imaging: Part 2â€State-of-the-Art Clinical Applications and Opportunities for Improved Patient Care. Radiology, 2021, 299, 524-538.	7.3	29
29	Pulmonary Functional Imaging: Part 1â€State-of-the-Art Technical and Physiologic Underpinnings. Radiology, 2021, 299, 508-523.	7.3	29
30	Dark-Field Chest X-ray Imaging: An Evolving Technique in the Century-Old History of Chest X-ray Imaging. Radiology, 2021, 301, 396-397.	7.3	3
31	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. Journal of Thoracic Oncology, 2021, , .	1.1	21
32	Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, .	1.5	0
33	Interstitial Lung Abnormalities: State of the Art. Radiology, 2021, 301, 19-34.	7.3	63
34	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With <i>EGFR</i>-Mutant Nonâ€Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	3.0	4
35	Anatomical Basis for Pulmonary Functional Imaging. Medical Radiology, 2021, , 1-10.	0.1	0
36	Future of Pulmonary Functional Imaging. Medical Radiology, 2021, , 337-360.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. <i>Journal of Thoracic Imaging</i> , 2020, 35, 101-107.	1.5	7
38	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 132, 109275.	2.6	13
39	Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality. <i>European Journal of Radiology</i> , 2020, 129, 109073.	2.6	38
40	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	7.3	70
41	Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders: Fleischner Society Position Paper. <i>Radiology</i> , 2020, 297, 286-301.	7.3	95
42	The Framingham Heart Study: Populational CT-based phenotyping in the lungs and mediastinum. <i>European Journal of Radiology Open</i> , 2020, 7, 100260.	1.6	5
43	Hiatus hernia and interstitial lung abnormalities. <i>European Respiratory Journal</i> , 2020, 56, 2001679.	6.7	6
44	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. <i>European Journal of Radiology Open</i> , 2020, 7, 100210.	1.6	4
45	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <i>Lancet Respiratory Medicine</i> , 2020, 8, 726-737.	10.7	279
46	The Associations of Interstitial Lung Abnormalities with Cancer Diagnoses and Mortality. <i>European Respiratory Journal</i> , 2020, 56, 1902154.	6.7	24
47	Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. <i>Lung Cancer</i> , 2020, 145, 132-139.	2.0	20
48	Projected lung areas using dynamic X-ray (DXR). <i>European Journal of Radiology Open</i> , 2020, 7, 100263.	1.6	14
49	Subsolid pulmonary nodules: Controversy and perspective. <i>European Journal of Radiology Open</i> , 2020, 7, 100267.	1.6	8
50	Simple quantitative chest CT for pulmonary edema. <i>European Journal of Radiology Open</i> , 2020, 7, 100273.	1.6	14
51	Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences. <i>European Journal of Radiology Open</i> , 2020, 7, 100291.	1.6	5
52	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	7.3	45
53	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1402-1413.	5.6	77
54	Radiographic pulmonary vessel volume, lung function and airways disease in the Framingham Heart Study. <i>European Respiratory Journal</i> , 2019, 54, 1900408.	6.7	28

#	ARTICLE	IF	CITATIONS
55	Detection of unwarranted CT radiation exposure from patient and imaging protocol meta-data using regularized regression. <i>European Journal of Radiology Open</i> , 2019, 6, 206-211.	1.6	6
56	Inter-observer agreement in identifying traction bronchiectasis on computed tomography: its improvement with the use of the additional criteria for chronic fibrosing interstitial pneumonia. <i>Japanese Journal of Radiology</i> , 2019, 37, 773-780.	2.4	10
57	M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. <i>Oncologist</i> , 2019, 24, e749-e754.	3.7	5
58	Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 175-183.	5.6	142
59	Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. <i>European Journal of Radiology Open</i> , 2019, 6, 128-131.	1.6	23
60	Significance of the Reverse Halo Sign in Immunocompromised Patients. <i>American Journal of Roentgenology</i> , 2019, 213, 549-554.	2.2	22
61	The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2019, 132, 79-86.	2.0	28
62	Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. <i>European Journal of Radiology</i> , 2019, 113, 59-65.	2.6	22
63	Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. <i>European Journal of Radiology</i> , 2019, 112, 28-36.	2.6	33
64	Objectively Measured Chronic Lung Injury on Chest CT. <i>Chest</i> , 2019, 156, 1149-1159.	0.8	9
65	Reply to "The Reversed Halo Sign: Criteria for Differentiation of Infectious and Noninfectious Diseases". <i>American Journal of Roentgenology</i> , 2019, 213, W296-W296.	2.2	0
66	Deep Learning Applications in Chest Radiography and Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2019, 34, 75-85.	1.5	90
67	Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2019, 16, 447-454.	3.2	20
68	Interstitial Lung Abnormality: Recognition and Perspectives. <i>Radiology</i> , 2019, 291, 1-3.	7.3	70
69	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	7.3	147
70	Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. <i>Human Pathology</i> , 2019, 86, 93-101.	2.0	19
71	Pulmonary Mucormycosis: Radiologic Features at Presentation and Over Time. <i>American Journal of Roentgenology</i> , 2018, 210, 742-747.	2.2	54
72	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018, 6, 630-635.	3.4	59

#	ARTICLE	IF	CITATIONS
73	Association between acute respiratory disease events and the <i>MUC5B</i> promoter polymorphism in smokers. Thorax, 2018, 73, 1071-1074.	5.6	13
74	Interstitial lung abnormalities and self-reported health and functional status. Thorax, 2018, 73, 884-886.	5.6	18
75	MRI for solitary pulmonary nodule and mass assessment: Current state of the art. Journal of Magnetic Resonance Imaging, 2018, 47, 1437-1458.	3.4	35
76	<sc>PD</sc>-inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. British Journal of Haematology, 2018, 180, 752-755.	2.5	18
77	Disease Severity Dependence of the Longitudinal Association Between CT Lung Density and Lung Function in Smokers. Chest, 2018, 153, 638-645.	0.8	16
78	Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 955-958.	5.6	78
79	Author reply: Response to: Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features™ by Araki <i>et al</i>. Occupational and Environmental Medicine, 2018, 75, 77.2-78.	2.8	1
80	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. European Journal of Radiology, 2018, 109, 68-76.	2.6	8
81	Interstitial lung abnormalities and physical function. ERJ Open Research, 2018, 4, 00057-2018.	2.6	9
82	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer, 2018, 123, 60-69.	2.0	58
83	Reply to "The Importance of the Reversed Halo Sign in the Diagnosis of Pulmonary Mucormycosis". American Journal of Roentgenology, 2018, 211, W138-W138.	2.2	0
84	Interstitial Features at Chest CT Enhance the Deleterious Effects of Emphysema in the COPD Gene Cohort. Radiology, 2018, 288, 600-609.	7.3	37
85	Magnetic resonance angiography for the primary diagnosis of pulmonary embolism: A review from the international workshop for pulmonary functional imaging. World Journal of Radiology, 2018, 10, 52-64.	1.1	22
86	Pneumonitis in advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI): Meta-analysis of 153 trial cohorts with 15,713 pts. Journal of Clinical Oncology, 2018, 36, e21223-e21223.	1.6	0
87	Time-Resolved Quantitative Analysis of the Diaphragms During Tidal Breathing in a Standing Position Using Dynamic Chest Radiography with a Flat Panel Detector System ("Dynamic X-Ray Phrenicography"). Academic Radiology, 2017, 24, 393-400.	2.5	32
88	Difference in diaphragmatic motion during tidal breathing in a standing position between COPD patients and normal subjects: Time-resolved quantitative evaluation using dynamic chest radiography with flat panel detector system ("dynamic X-ray phrenicography"). European Journal of Radiology, 2017, 87, 76-82.	2.6	37
89	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. European Journal of Radiology, 2017, 88, 15-20.	2.6	15
90	Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 138-141.	5.6	44

#	ARTICLE	IF	CITATIONS
91	Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns. <i>Journal of Clinical Oncology</i> , 2017, 35, 1628-1629.	1.6	19
92	Difference in the craniocaudal gradient of the maximum pixel value change rate between chronic obstructive pulmonary disease patients and normal subjects using sub-mGy dynamic chest radiography with a flat panel detector system. <i>European Journal of Radiology</i> , 2017, 92, 37-44.	2.6	13
93	Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features. <i>Occupational and Environmental Medicine</i> , 2017, 74, 756-761.	2.8	11
94	Clinical and Genetic Associations of Objectively Identified Interstitial Changes in Smokers. <i>Chest</i> , 2017, 152, 780-791.	0.8	37
95	Lung Mass in Smokers. <i>Academic Radiology</i> , 2017, 24, 386-392.	2.5	15
96	The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. <i>Academic Radiology</i> , 2017, 24, 941-946.	2.5	37
97	The <i>MUC5B</i> promoter polymorphism is associated with specific interstitial lung abnormality subtypes. <i>European Respiratory Journal</i> , 2017, 50, 1700537.	6.7	55
98	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	3.3	56
99	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	7.0	69
100	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	27.6	787
101	Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques. <i>European Journal of Radiology</i> , 2017, 86, 313-319.	2.6	14
102	Screening for lung cancer: Does MRI have a role?. <i>European Journal of Radiology</i> , 2017, 86, 353-360.	2.6	62
103	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	3.0	35
104	Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting. <i>Journal of Clinical Oncology</i> , 2017, 35, 9087-9087.	1.6	1
105	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2016, 4, 84.		94
106	Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality. <i>European Journal of Radiology Open</i> , 2016, 3, 86-94.	1.6	33
107	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	7.0	393
108	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	7.1	600

#	ARTICLE	IF	CITATIONS
109	Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1514-1522.	5.6	233
110	Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. European Radiology, 2016, 26, 15-24.	4.5	57
111	Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterizationâ€”iLEAD study. European Journal of Radiology Open, 2016, 3, 67-73.	1.6	30
112	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	7.4	333
113	Antiâ€”PD-1 Inhibitorâ€”Related Pneumonitis in Nonâ€”Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	3.4	135
114	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic Radiology, 2016, 23, 329-336.	2.5	33
115	Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. European Journal of Cancer, 2016, 53, 163-170.	2.8	45
116	PD-1 inhibitor-related pneumonitis in advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 3053-3053.	1.6	3
117	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	2.0	39
118	Paraseptal emphysema: Prevalence and distribution on CT and association with interstitial lung abnormalities. European Journal of Radiology, 2015, 84, 1413-1418.	2.6	42
119	Anterior mediastinal masses in the Framingham Heart Study: Prevalence and CT image characteristics. European Journal of Radiology Open, 2015, 2, 26-31.	1.6	46
120	Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. European Journal of Radiology, 2015, 84, 998-1004.	2.6	54
121	Pulmonary cysts identified on chest CT: are they part of aging change or of clinical significance?. Thorax, 2015, 70, 1156-1162.	5.6	48
122	Antiâ€”PD-1â€”Related Pneumonitis during Cancer Immunotherapy. New England Journal of Medicine, 2015, 373, 288-290.	27.0	339
123	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist, 2015, 20, 1077-1083.	3.7	46
124	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.8	78
125	Lung parenchymal signal intensity in MRI: A technical review with educational aspirations regarding reversible versus irreversible transverse relaxation effects in common pulse sequences. Concepts in Magnetic Resonance Part A: Bridging Education and Research, 2014, 43A, 29-53.	0.5	33
126	Pulmonary hyperpolarized noble gas MRI: Recent advances and perspectives in clinical application. European Journal of Radiology, 2014, 83, 1282-1291.	2.6	43

#	ARTICLE	IF	CITATIONS
127	Thymic Measurements in Pathologically Proven Normal Thymus and Thymic Hyperplasia. <i>Academic Radiology</i> , 2014, 21, 733-742.	2.5	14
128	A practical approach to high-resolution CT of diffuse lung disease. <i>European Journal of Radiology</i> , 2014, 83, 6-19.	2.6	57
129	Radiation dose reduction in chest CT—Review of available options. <i>European Journal of Radiology</i> , 2014, 83, 1953-1961.	2.6	80
130	State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine. <i>Radiology</i> , 2014, 271, 6-27.	7.3	114
131	Interstitial lung abnormalities in treatment-naïve advanced NSCLC patients (pts): Prevalence and impact on survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19030-e19030.	1.6	1
132	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2013, 119, 3761-3768.	4.1	40
133	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013, 79, 283-288.	2.0	68
134	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0. <i>American Journal of Roentgenology</i> , 2013, 201, W64-W71.	2.2	39
135	MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities. <i>New England Journal of Medicine</i> , 2013, 368, 2192-2200.	27.0	358
136	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-small-Cell Lung Cancer Patients Treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1059-1068.	1.1	48
137	Volumetric tumor growth in advanced NSCLC patients (pts) with EGFR mutations during EGFR-TKI therapy: Developing criteria to define slow progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19125-e19125.	1.6	0
138	Interstitial Lung Abnormalities and Reduced Exercise Capacity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 756-762.	5.6	106
139	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	2.2	169
140	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7553-7553.	1.6	0
141	Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. <i>New England Journal of Medicine</i> , 2011, 364, 897-906.	27.0	468
142	CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer. <i>Academic Radiology</i> , 2011, 18, 54-62.	2.5	83
143	Imaging of Lung Cancer in the Era of Molecular Medicine. <i>Academic Radiology</i> , 2011, 18, 424-436.	2.5	37
144	New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. <i>American Journal of Roentgenology</i> , 2010, 195, W221-W228.	2.2	182

#	ARTICLE	IF	CITATIONS
145	Identification of Early Interstitial Lung Disease in Smokers from the COPD Gene Study. <i>Academic Radiology</i> , 2010, 17, 48-53.	2.5	175
146	Low dose multi-detector CT of the chest (iLEAD Study): Visual ranking of different simulated mAs levels. <i>European Journal of Radiology</i> , 2010, 73, 428-433.	2.6	16
147	Vascular Enhancement and Image Quality of MDCT Pulmonary Angiography in 400 Cases: Comparison of Standard and Low Kilovoltage Settings. <i>American Journal of Roentgenology</i> , 2009, 192, 1651-1656.	2.2	67
148	Functional MR Imaging of the Lung. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2008, 16, 275-289.	1.1	23
149	Radiation Dose Reduction in Chest CT: A Review. <i>American Journal of Roentgenology</i> , 2008, 190, 335-343.	2.2	257
150	Use of 3D Adaptive Raw-Data Filter in CT of the Lung: Effect on Radiation Dose Reduction. <i>American Journal of Roentgenology</i> , 2008, 191, W167-W174.	2.2	22
151	Primary Pulmonary Hypertension: 3D Dynamic Perfusion MRI for Quantitative Analysis of Regional Pulmonary Perfusion. <i>American Journal of Roentgenology</i> , 2007, 188, 48-56.	2.2	108
152	Basics concepts and clinical applications of oxygen-enhanced MR imaging. <i>European Journal of Radiology</i> , 2007, 64, 320-328.	2.6	55
153	Hyperpolarized ¹²⁹ Xe MRI: A viable functional lung imaging modality?. <i>European Journal of Radiology</i> , 2007, 64, 335-344.	2.6	130
154	Correlation Between Image Noise and Body Weight in Coronary CTA with 16-row MDCT. <i>Academic Radiology</i> , 2006, 13, 324-328.	2.5	47
155	3-Dimensional Adaptive Raw-Data Filter. <i>Journal of Computer Assisted Tomography</i> , 2006, 30, 933-938.	0.9	16
156	Quantitative analysis of the velocity and synchronicity of diaphragmatic motion: dynamic MRI in different postures. <i>Magnetic Resonance Imaging</i> , 2006, 24, 1325-1332.	1.8	61
157	Oxygen-enhanced MR Imaging: Correlation with Postsurgical Lung Function in Patients with Lung Cancer. <i>Radiology</i> , 2005, 236, 704-711.	7.3	71
158	Metastases in Mediastinal and Hilar Lymph Nodes in Patients with Non-Small Cell Lung Cancer: Quantitative and Qualitative Assessment with STIR Turbo Spin-Echo MR Imaging. <i>Radiology</i> , 2004, 231, 872-879.	7.3	118
159	MR Angiography with Sensitivity Encoding (SENSE) for Suspected Pulmonary Embolism: Comparison with MDCT and Ventilation-Perfusion Scintigraphy. <i>American Journal of Roentgenology</i> , 2004, 183, 91-98.	2.2	121
160	Quantitative assessment of regional pulmonary perfusion in the entire lung using three-dimensional ultrafast dynamic contrast-enhanced magnetic resonance imaging: Preliminary experience in 40 subjects. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 353-365.	3.4	189
161	Architecture of the Lung. <i>Journal of Thoracic Imaging</i> , 2004, 19, 221-227.	1.5	47
162	Time-resolved contrast-enhanced pulmonary MR angiography using sensitivity encoding (SENSE). <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 330-336.	3.4	59

#	ARTICLE	IF	CITATIONS
163	Characterization of regional pulmonary mechanics from serial magnetic resonance imaging data 1. <i>Academic Radiology</i> , 2003, 10, 1147-1152.	2.5	57
164	Clinical Oxygen-Enhanced Magnetic Resonance Imaging of the Lung. <i>Topics in Magnetic Resonance Imaging</i> , 2003, 14, 237-243.	1.2	26
165	Solitary Pulmonary Nodules: Potential Role of Dynamic MR Imaging in Management—Initial Experience. <i>Radiology</i> , 2002, 224, 503-511.	7.3	142
166	CT and MR in pulmonary embolism: A changing role for nuclear medicine in diagnostic strategy. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 183-192.	4.6	16
167	MR-pathologic correlation of lung specimens. <i>European Journal of Radiology</i> , 2002, 44, 210-215.	2.6	3
168	Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. <i>European Journal of Radiology</i> , 2002, 44, 216-224.	2.6	55
169	Dynamic oxygen-enhanced MRI reflects diffusing capacity of the lung. <i>Magnetic Resonance in Medicine</i> , 2002, 47, 1139-1144.	3.0	99
170	Pulmonary ventilation: dynamic MRI with inhalation of molecular oxygen. <i>European Journal of Radiology</i> , 2001, 37, 172-178.	2.6	64
171	Structural basis for pulmonary functional imaging. <i>European Journal of Radiology</i> , 2001, 37, 143-154.	2.6	12
172	Dynamic observation of pulmonary perfusion using continuous arterial spin-labeling in a pig model. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 175-180.	3.4	23
173	Evaluation of regional pulmonary perfusion using ultrafast magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2001, 46, 166-171.	3.0	116
174	Pulmonary MR angiography with contrast agent at 4 Tesla: A preliminary result. <i>Magnetic Resonance in Medicine</i> , 2001, 46, 1028-1030.	3.0	18
175	Multiphase ECG-triggered 3D contrast-enhanced MR angiography: Utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 13, 215-224.	3.4	85
176	Oxygen-Enhanced MR Ventilation Imaging of the Lung. <i>American Journal of Roentgenology</i> , 2001, 177, 185-194.	2.2	89
177	Noninvasive pulmonary perfusion imaging by STAR-HASTE sequence. <i>Magnetic Resonance in Medicine</i> , 2000, 44, 808-812.	3.0	38
178	Pulmonary Disorders: Ventilation-Perfusion MR Imaging with Animal Models. <i>Radiology</i> , 1999, 213, 871-879.	7.3	87
179	Quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 1999, 42, 1033-1038.	3.0	170
180	MR imaging of pulmonary parenchyma with a half-Fourier single-shot turbo spin-echo (HASTE) sequence. <i>European Journal of Radiology</i> , 1999, 29, 152-159.	2.6	121

#	ARTICLE	IF	CITATIONS
181	T2* and proton density measurement of normal human lung parenchyma using submillisecond echo time gradient echo magnetic resonance imaging. <i>European Journal of Radiology</i> , 1999, 29, 245-252.	2.6	168
182	Fast magnetic resonance imaging of the lung. <i>European Journal of Radiology</i> , 1999, 29, 114-132.	2.6	82
183	Oxygen enhanced MR ventilation imaging of the lung. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 1998, 7, 153-161.	2.0	96
184	Effect of oxygen inhalation on relaxation times in various tissues. <i>Journal of Magnetic Resonance Imaging</i> , 1997, 7, 220-225.	3.4	165
185	Pulmonary perfusion: Qualitative assessment with dynamic contrast-enhanced MRI using ultra-shortTE and inversion recovery turbo FLASH. <i>Magnetic Resonance in Medicine</i> , 1996, 36, 503-508.	3.0	218
186	Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. <i>Nature Medicine</i> , 1996, 2, 1236-1239.	30.7	397
187	Multi-Slice, Breathhold Imaging of the Lung with Submillisecond Echo Times. <i>Magnetic Resonance in Medicine</i> , 1995, 33, 678-682.	3.0	105
188	Cavities in the lung in oncology patients: Imaging overview and differential diagnoses. , 0, , 10-21.		12